Polaris Market Research
Central Nervous System Therapeutics Market Growth, Trends, Global Forecast, 2025-2034
Inquire Before Buying Request Free Sample
Central Nervous System Therapeutics Market Growth, Trends, Global Forecast, 2025-2034

Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034

  • Published Date:Feb-2025
  • Pages: 125
  • Format: PDF
  • Report ID: PM5368
  • Base Year: 2024
  • Historical Data: 2020-2023

Central Nervous System Therapeutics Market Overview

The global central nervous system therapeutics market size was valued at USD 141.09 billion in 2024. The market is projected to grow from USD 155.52 billion in 2025 to USD 381.27 billion by 2034, exhibiting a CAGR of 10.5% from 2025 to 2034.

Central nervous system therapeutics refer to a class of treatments for disorders affecting the brain and spinal cord, including conditions like depression, schizophrenia, epilepsy, and neurodegenerative diseases. These therapeutics include medications, such as antidepressants and antipsychotics, as well as other interventions, like neuromodulation techniques and behavioral therapies.

The demand for central nervous system (CNS) therapeutics is rising as the prevalence of CNS disorders continues to increase. Conditions such as depression, anxiety, Alzheimer’s disease, and multiple sclerosis are being diagnosed more frequently, leading to increasing demand for effective treatments. For example, the Parkinson's Foundation reports that approximately 90,000 new Parkinson's disease cases are diagnosed annually in the US, highlighting the growing burden of CNS disorders. This surge in diagnoses is a key factor propelling the CNS therapeutics market growth.

To Understand More About this Research: Request a Free Sample Report

The central nervous system therapeutics market demand is being driven by strong regulatory support for drug approvals. Regulatory agencies, such as the FDA, have improved their processes to facilitate faster approvals for new treatments, particularly for serious CNS disorders. For instance, in November 2023, the US FDA granted fast-track designation for RZ-001 for the treatment of patients with glioblastoma, an invasive glioma in the brain. This regulatory support encourages pharmaceutical companies to invest more in research and development. Additionally, initiatives like breakthrough designations and priority review programs help speed up the approval process for new drugs, making it easier for patients to access effective treatments and driving market growth.

Central Nervous System Therapeutics Market Dynamics

Rising Geriatric Population Worldwide

Individuals aged 50 and older are more susceptible to neurological and mental health conditions such as Alzheimer’s disease, dementia, and depression. For instance, in 2020, the Organization for Economic Co-operation and Development reported that the share of the population aged 65 and above had increased to 17.96%. This demographic shift has prompted healthcare systems to focus on enhancing care for older adults, leading to greater investment in the research and development of CNS therapies. Thus, the rising number of elderly individuals is increasing the demand for innovative solutions to manage age-related health issues, thereby fueling the central nervous system therapeutics market development.

Increasing Investments in Mental Health

Growing awareness of mental health issues is prompting governments, organizations, and private investors to invest significantly in effective treatments. For instance, according to the Keshav Desiraju India Mental Health Observatory, the Indian government allocated USD 144.46 million in the annual budget for 2023–2024 to address mental health-related disorders. This boost in funding supports research and innovation in drug development, leading to new therapies for conditions such as depression, anxiety, and neurodegenerative disorders. Consequently, the increased investment in mental health is boosting the central nervous systems therapeutics market revenue.

Central Nervous System Therapeutics Market Segment Insights

Central Nervous System Therapeutics Market Evaluation by Drug Class Insights

The central nervous system therapeutics market segmentation, based on drug class, includes anesthetics, anticonvulsants, antiemetics, CNS stimulants, pain relievers, and others. The CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market. This growth is due to the rising prevalence of attention deficit hyperactivity disorder (ADHD) and sleep disorders, both of which are neurological conditions linked to CNS dysfunction and affect billions worldwide. For instance, according to the National Institute of Health, ADHD affects 5-7.2% of youth globally. Increasing awareness and improved diagnosis of these conditions are leading to greater demand for effective treatments, leading to segment growth in the global market.

Central Nervous System Therapeutics Market Assessment by Distribution Channel Insights

The central nervous system therapeutics market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominated the central nervous system therapeutics market in 2024 due to the rising number of hospital admissions for neurodegenerative diseases, such as Alzheimer's and Parkinson's. Hospital pharmacies provide access to essential CNS medications for patients who require specialized care and treatment for this condition.

Central Nervous System Therapeutics Market Regional Analysis

By region, the study provides the central nervous system therapeutics market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America had the largest revenue share in the central nervous system therapeutics market due to the rising prevalence of Alzheimer’s disease. More individuals are being diagnosed with this condition, leading to increased demand for effective treatments. For instance, according to the Alzheimer's Association, in 2023, nearly 7 million Americans are living with Alzheimer's, and by 2050 it is projected to rise to 13 million. This rising patient population is encouraging pharmaceutical companies to invest in research and development of new therapies. Additionally, increased awareness about Alzheimer's and initiatives aimed at early detection of the disease are driving the demand for central nervous systems therapeutics, positively impacting the regional market growth.

Asia Pacific is experiencing significant growth in the global market, driven by increased government investment in healthcare. Many Asian nations are prioritizing healthcare advancements, leading to higher funding for research and development of treatments for central nervous system disorders. China launched a major initiative aimed at enhancing its healthcare system. As part of this effort, in September 2024, China’s Ministry of Commerce (MOFCOM), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) issued a joint Circular outlining pilot programs to open the country's healthcare sector to foreign investors. The Circular details plans to establish wholly foreign-owned hospitals in cities like Beijing and Shanghai. This initiative is expected to boost investment, accelerating the development of therapies for conditions like depression and neurodegenerative diseases, thus fueling the central nervous system therapeutics market growth in the Asia Pacific.

The India central nervous system therapeutics market is experiencing substantial growth, driven by the expansion of the pharmaceutical industry. With many companies focusing on producing a variety of medicines, including those for mental health and neurological disorders, patients now have better access to effective treatments. This growth is further supported by increased investment in research and development, leading to the creation of innovative therapies.

Central Nervous System Therapeutics Market – Key Players and Competitive Insights

The central nervous system therapeutics market is constantly evolving, with numerous companies striving to innovate and distinguish themselves. Leading global corporations dominate the market by leveraging extensive research and development, and advanced techniques. These companies pursue strategic initiatives such as mergers and acquisitions, partnerships, and collaborations to enhance their product offerings and expand into new markets.

New companies are impacting the market by introducing innovative products to meet the demand of specific market sectors. This competitive environment is amplified by continuous progress in product offerings. Major players in the central nervous system therapeutics market include Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

Novartis AG is a healthcare company that specializes in the development and manufacture of generic pharmaceuticals and eye care products. With a global presence in 140 countries, it offers a wide range of products for the treatment of various medical conditions, including cancer, neurological disorders, cardiovascular diseases, respiratory diseases, hematologic diseases, immune disorders, infections, and dermatological conditions. The company has a strong focus on therapeutic areas such as renal, metabolic, cardiovascular, neuroscience, immunology, and oncology, as well as ophthalmology and hematology. The company has a collaboration and license agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The Innovative Medicines division is responsible for researching, developing, manufacturing, distributing, and selling patented pharmaceuticals. This segment comprises two business units: Novartis Pharmaceuticals and Novartis Oncology. These units are dedicated to bringing new and innovative treatments to patients suffering from various diseases, including cancer, cardiovascular diseases, and neurological disorders. Also, Novartis AG offers CNS therapeutics like Gilenya (MS), Aimovig (migraine), Exelon (Alzheimer's), and Stalevo (Parkinson’s), while expanding its neuroscience pipeline through acquisitions and collaborations in gene and RNA-based therapies.

Bottom of Form

Johnson & Johnson Services, Inc. is a multinational corporation based in New Brunswick, New Jersey, USA. The company operates through pharmaceuticals, medical devices, and consumer health products operations. The company's subsidiary, Janssen Pharmaceuticals, Inc., develops and markets drugs in various therapeutic areas, including neuroscience, oncology, infectious diseases, and immunology. Janssen Pharmaceuticals, Inc. creates many well-known drugs, such as Risperdal (risperidone), Remicade (infliximab), and Zytiga (abiraterone). Johnson & Johnson's CNS therapeutics include Concerta (ADHD) and Caplyta (schizophrenia, bipolar disorder). The recent acquisition of Intra-Cellular Therapies enhances their mental health treatment portfolio. The company also has a consumer health division, which develops and markets over-the-counter products such as Band-Aids, Tylenol, and Listerine. The company's consumer health business includes subsidiaries such as Neutrogena, Aveeno, and Johnson's Baby. The company was founded in 1886. Johnson & Johnson sells its products under the brand The DePuy Synthes, an orthopedic company that was acquired in 1998.

Top of Form

Bottom of Form

List of Key Companies in Central Nervous System Therapeutics Market

  • Biogen
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Astra Zeneca
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson, Inc.
  • Pfizer Inc.

Central Nervous System Therapeutics Industry Developments

May 2024: Teva Pharmaceuticals announced the FDA approval of AUSTEDO XR as a once-daily treatment for tardive dyskinesia and Huntington’s disease chorea, featuring four new tablet strengths. The company stated that the approval marks a significant advancement in the management of these chronic movement disorders.Top of Form

May 2024: An exclusive worldwide option and license agreement was announced between Takeda and AC Immune for the development of ACI-24.060, an active immunotherapy targeting toxic amyloid beta forms, aimed at treating Alzheimer’s disease and potentially slowing its progression.Bottom of Form

June JMarch MNoNOTop of Form

Bottom of Form

Bottom of Form

Bottom of Form

Central Nervous System Therapeutics Market Segmentation

By Disease Outlook (USD Billion, 2020–2034)

  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
  • Neurodegenerative Diseases
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntington’s Disease
  • Amyotrophic Lateral Sclerosis
  • Others
  • Infectious Diseases
  • CNS Cancer
  • Others

By Drug Class Outlook (USD Billion, 2020–2034)

  • Anesthetics
  • Anticonvulsants
  • Antiemetics
  • CNS Stimulants
  • Pain Relievers
  • Others

By Distribution Channel Outlook (USD Billion, 2020–2034)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (USD Billion, 2020–2034)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Netherlands
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Malaysia
    • South Korea
    • Indonesia
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America

Central Nervous System Therapeutics Market Report Scope

Report Attributes

Details

Market Size Value in 2024

USD 141.09 billion

Market Size Value in 2025

USD 155.52 billion

Revenue Forecast by 2034

USD 381.27 billion

CAGR

10.5% from 2025–2034

Base Year

2024

Historical Data

2020–2023

Forecast Period

2025–2034

Quantitative Units

Revenue in USD billion and CAGR from 2025 to 2034

Report Coverage

Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends

Segments Covered
  • By Disease
  • By Drug Class
  • By Distribution Channel

Regional Scope
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape
  • Central Nervous System Therapeutics Industry Trends Analysis (2024)
  • Company profiles/industry participants profiling includes company overview, financial information, product/services benchmarking, and recent developments

Report Format
  • PDF + Excel

Customization

Report customization as per your requirements with respect to countries, regions, and segmentation.

FAQ's

• The central nervous system therapeutics market size was valued at USD 141.09 billion in 2024 and is projected to grow to USD 381.27 billion by 2034.

• The global market is projected to register a CAGR of 10.5% from 2025 to 2034.

• North America had the largest share of the global market in 2024.

• A few of the key players in the market are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

• The CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market due to the rising prevalence of attention deficit hyperactivity disorder (ADHD) and sleep disorders.

• The hospital pharmacies segment dominated the central nervous system therapeutics market in 2024 due to the rising number of hospital admissions for neurodegenerative diseases, such as Alzheimer's and Parkinson's.

© 2025 Polaris Market Research and Consulting. All rights reserved

paypal